Sharescart Research Club logo

Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹2707 Cr.
Stock P/E
19.8
P/B
2
Current Price
₹488.7
Book Value
₹ 240.7
Face Value
2
52W High
₹767.6
52W Low
₹ 372.9
Dividend Yield
0.1%

Rossari Biotech Overview

Business

Rossari Biotech Ltd. is an India-based specialty chemicals manufacturer providing a diverse range of products across various industrial applications. Its core business model involves developing, manufacturing, and supplying innovative and sustainable chemical solutions to a wide array of B2B customers. The company emphasizes in-house research and development to create customized products that meet specific client requirements. Rossari makes money by selling these value-added specialty chemicals to industries such as textiles, animal health & nutrition, home & personal care, construction, paints, and agrochemicals.

Revenue Mix

Rossari Biotech operates primarily across three key segments:

Textile Specialty Chemicals: This segment includes a comprehensive range of products for the entire textile processing value chain, from pre-treatment to finishing. This has historically been a significant revenue contributor.

Animal Health & Nutrition: Focused on poultry, aqua, and dairy sectors, offering products like feed supplements, probiotics, and disinfectants.

Home, Personal Care & Performance Chemicals (HPPC): This segment caters to various industries, providing ingredients for detergents, soaps, cosmetics, industrial cleaners, water treatment, and also expanding into construction chemicals, paints, and agrochemicals.

The company's strategy has been to diversify its revenue mix away from a heavy reliance on the textile sector towards faster-growing areas like HPPC and Animal Health. While specific current percentages can fluctuate, the trend is towards a more balanced contribution from these diversified segments.

Industry

The Indian specialty chemicals industry is characterized by its diversity, fragmented nature, and strong link to end-user industry growth. It is largely driven by R&D, application-specific solutions, and import substitution opportunities. Rossari Biotech is positioned as a mid-tier player within this competitive landscape, known for its strong R&D capabilities, diversified product portfolio, and focus on sustainable solutions. It competes with both large domestic chemical manufacturers and smaller, specialized players, as well as global chemical majors operating in India. The company leverages its technical expertise and customer-centric approach to differentiate itself.

MOAT

Strong R&D and Customization Capabilities: Rossari's in-house R&D enables it to develop tailor-made, application-specific chemical solutions, fostering stickiness with customers who rely on these specialized products.

Diversified Product Portfolio & End-User Industries: Its presence across multiple segments (Textiles, Animal Health, HPPC, Construction, etc.) reduces dependence on any single industry's cycles, offering resilience and broader growth avenues.

Customer Relationships: Long-standing relationships with key clients, built on product quality, technical support, and consistent supply, contribute to recurring business.

Operational Efficiency: Continuous focus on process improvement and capacity utilization helps in cost management and competitive pricing.

Growth Drivers

Diversification into New End-User Industries: Continued penetration and expansion in high-growth areas like construction chemicals, agrochemicals, paints, and advanced HPPC applications.

Capacity Expansion: Commissioning of new manufacturing facilities or expanding existing ones to meet growing demand and scale operations.

Increased Demand for Specialty Chemicals: Driven by industrial growth, urbanization, rising disposable incomes in India, and the trend of import substitution.

Focus on Sustainable Solutions: Growing preference for eco-friendly and green chemistry products offers a differentiation and growth avenue.

Acquisitions & Strategic Alliances: Inorganically expanding product lines, technologies, or market reach through strategic mergers and acquisitions.

Risks

Raw Material Price Volatility: Many specialty chemicals rely on crude oil derivatives and other commodities, making margins susceptible to fluctuations in raw material prices.

Intense Competition: The specialty chemicals sector is highly competitive, facing challenges from both domestic players and larger global manufacturers.

Regulatory & Environmental Compliance: Strict and evolving environmental regulations, chemical safety norms, and manufacturing permits can impact operations and costs.

Economic Slowdown: A downturn in key end-user industries (e.g., textiles, construction) could lead to reduced demand for the company's products.

R&D Success: Failure to continuously innovate and develop new, relevant products could lead to loss of competitive edge.

Foreign Exchange Fluctuations: For imported raw materials or export revenues.

Management & Ownership

Rossari Biotech was founded by Mr. Edward Menezes and Mr. Sunil Chari, who continue to serve as the Executive Directors and key promoters of the company. They bring significant experience and technical expertise in the chemical industry. The management is generally perceived as committed to R&D-driven growth and strategic diversification. The ownership structure typically includes a significant promoter holding, alongside institutional investors, high net-worth individuals, and public shareholders.

Outlook

Rossari Biotech is positioned to benefit from the growing demand for specialty chemicals in India, driven by industrial expansion and increasing consumption. Its strong R&D focus, diversified product portfolio, and strategic capacity expansions provide a solid foundation for growth. The company's efforts to de-risk its revenue mix by expanding beyond textiles into high-growth segments like Animal Health and HPPC are positive. However, the business faces inherent risks such as volatility in raw material prices, intense competition, and potential regulatory changes. The ability to successfully integrate acquisitions, maintain innovation, and navigate cost pressures will be crucial for sustained profitability and market share gains in the long term.

Rossari Biotech Share Price

Live · BSE / NSE · Inception: 2003
| |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Rossari Biotech Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 464 473 490 498 513 580 544 586 582 685
Other Income 4 0 1 1 1 2 1 2 1 19
Total Income 467 473 491 499 513 581 545 588 582 704
Total Expenditure 400 409 425 432 448 510 476 514 513 608
Operating Profit 67 64 66 67 65 71 69 74 69 96
Interest 4 3 4 4 5 6 6 6 8 9
Depreciation 15 16 15 15 18 18 18 18 20 24
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 48 45 47 48 42 48 46 49 42 64
Provision for Tax 13 11 12 13 11 13 13 13 10 18
Profit After Tax 34 34 35 35 31 34 33 36 32 45
Adjustments 0 0 0 0 0 0 1 0 0 1
Profit After Adjustments 34 34 35 35 32 34 34 37 33 46
Adjusted Earnings Per Share 6.2 6.2 6.3 6.4 5.7 6.2 6.1 6.7 5.9 8.3

Rossari Biotech Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 171 179 233 292 516 600 709 1483 1656 1831 2080 2397
Other Income 0 0 1 1 1 4 9 19 14 14 15 23
Total Income 171 179 234 293 517 604 719 1502 1670 1845 2095 2419
Total Expenditure 156 166 209 247 439 495 586 1307 1441 1587 1826 2111
Operating Profit 15 13 25 46 78 108 132 195 229 257 269 308
Interest 5 4 2 1 3 4 3 13 22 19 18 29
Depreciation 5 5 4 5 12 17 23 48 63 60 67 80
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 5 5 19 40 63 88 107 136 144 178 185 201
Provision for Tax 1 1 3 11 18 23 27 39 37 47 49 54
Profit After Tax 4 3 16 29 46 65 80 98 107 131 136 146
Adjustments 0 0 0 0 0 0 0 -0 0 0 0 2
Profit After Adjustments 4 3 16 29 46 65 80 98 107 131 136 150
Adjusted Earnings Per Share 0.8 0.7 3.3 6 9.4 12.9 15.4 17.7 19.4 23.7 24.6 27

Rossari Biotech Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 47 50 65 94 124 287 409 805 915 1048 1185
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 9 7 2 1 1 34 0 0 35 33 100
Other Non-Current Liabilities 0 -0 -0 2 36 35 59 251 146 160 161
Total Current Liabilities 58 52 57 68 122 169 177 360 476 584 740
Total Liabilities 114 109 124 166 283 525 645 1417 1572 1825 2187
Fixed Assets 38 38 38 45 74 94 181 607 585 578 598
Other Non-Current Assets 8 8 9 15 49 85 82 135 138 243 342
Total Current Assets 69 63 77 106 160 346 381 675 847 1003 1246
Total Assets 114 109 124 166 283 525 645 1417 1572 1825 2187

Rossari Biotech Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 1 3 2 1 6 29 15 37 69 25
Cash Flow from Operating Activities 8 26 7 24 71 57 48 29 152 43 137
Cash Flow from Investing Activities -2 -5 -6 -20 -36 -190 -37 -299 -181 -103 -184
Cash Flow from Financing Activities -6 -19 -2 -5 -29 157 -25 292 61 16 65
Net Cash Inflow / Outflow 0 2 -0 -2 6 23 -14 22 32 -44 19
Closing Cash & Cash Equivalent 1 3 2 1 6 29 15 37 69 25 44

Rossari Biotech Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.77 0.7 3.25 5.99 9.44 12.86 15.45 17.74 19.45 23.66 24.63
CEPS(Rs) 1.82 1.63 4.13 7.06 11.96 16.18 19.81 26.47 30.86 34.59 36.75
DPS(Rs) 0.1 0 0 4 1 0.5 0.5 0.5 0.5 0.5 0.5
Book NAV/Share(Rs) 9.69 10.33 13.5 19.5 25.58 56.39 78.31 145.65 165.29 189.01 213.72
Core EBITDA Margin(%) 8.52 7.01 10.43 14.95 15.01 17.37 17.21 11.84 12.91 13.22 12.19
EBIT Margin(%) 5.72 4.69 9.03 13.69 12.83 15.15 15.36 10 10.02 10.71 9.74
Pre Tax Margin(%) 2.77 2.72 8.11 13.24 12.27 14.56 14.94 9.15 8.68 9.66 8.88
PAT Margin (%) 2.18 1.89 6.74 9.71 8.84 10.82 11.19 6.56 6.45 7.11 6.54
Cash Profit Margin (%) 5.15 4.42 8.57 11.44 11.2 13.61 14.38 9.78 10.24 10.39 9.76
ROA(%) 3.11 3.04 13.49 20 20.38 16.17 13.69 9.48 7.18 7.7 6.8
ROE(%) 8.18 6.99 27.27 36.33 41.88 31.83 23.11 16.17 12.52 13.36 12.25
ROCE(%) 10.7 10.3 26.4 40.37 54.4 37.93 28.81 24.37 18.48 18.39 16.07
Receivable days 61.77 61.97 61.34 65.53 51.48 54.48 60.78 55 72.29 77.31 78.74
Inventory Days 78.22 57.73 38.07 35.88 31.8 34.21 39.17 34.95 41.54 46.74 55.79
Payable days 68.05 65.27 66.35 67.16 78.74 99.66 90.07 52.27 57.21 56.45 64.36
PER(x) 0 0 0 0 0 0 67.17 51.49 30.61 28.51 24.52
Price/Book(x) 0 0 0 0 0 0 13.25 6.27 3.6 3.57 2.83
Dividend Yield(%) 0 0 0 0 0 0 0.05 0.05 0.08 0.07 0.08
EV/Net Sales(x) 0.27 0.13 0.1 0.08 0.01 -0.08 7.47 3.36 1.95 2.08 1.67
EV/Core EBITDA(x) 3.15 1.86 0.95 0.53 0.04 -0.46 40.08 25.51 14.15 14.78 12.91
Net Sales Growth(%) 10.37 4.44 30.64 25.02 76.91 16.25 18.21 109.06 11.66 10.55 13.64
EBIT Growth(%) -1.01 -14.44 151.42 94.16 62.02 37.92 20.17 35.6 11.82 18.29 3.05
PAT Growth(%) -2.03 -9.17 364.63 84.44 57.46 42.84 22.67 22.05 9.79 21.85 4.35
EPS Growth(%) -2.03 -9.17 364.63 84.44 57.46 36.21 20.15 14.85 9.61 21.65 4.13
Debt/Equity(x) 0.93 0.45 0.34 0.22 0.04 0.23 0 0.01 0.08 0.1 0.16
Current Ratio(x) 1.17 1.21 1.35 1.56 1.31 2.05 2.16 1.87 1.78 1.72 1.68
Quick Ratio(x) 0.63 0.73 0.94 1.04 0.86 1.71 1.62 1.35 1.39 1.23 1.2
Interest Cover(x) 1.94 2.38 9.85 30.15 23.03 25.7 36.71 11.77 7.46 10.17 11.4
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0.02 0.03 0.06

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +14% +12% +28% +28%
Operating Profit CAGR +5% +11% +20% +33%
PAT CAGR +4% +12% +16% +42%
Share Price CAGR -29% -17% -17%
ROE Average +12% +13% +15% +21%
ROCE Average +16% +18% +21% +26%

Rossari Biotech Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 68.15 %
FII 2.18 %
DII (MF + Insurance) 18.2 %
Public (retail) 31.85 %
# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 68.3368.3268.3268.2768.1968.1868.1768.1768.1668.15
FII 4.144.033.833.743.743.983.482.692.332.18
DII 18.0617.7516.8717.3417.4717.5917.8418.1818.2618.2
Public 31.6731.6831.6831.7331.8131.8231.8331.8331.8431.85
Others 0000000000
Total 100100100100100100100100100100

Rossari Biotech Peer Comparison

Chemicals Edit Columns

Rossari Biotech Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Rossari Biotech Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Company has a low return on equity of 13% over the last 3 years.
  • Debtor days have increased from 56.45 to 64.36days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp